The 3rd Global NASH Congress, London, UK

This two-day meeting has been purposely designed to facilitate collaboration and attract attendance from multiple stakeholders including KOL, investigators, academia, pharma, providers and regulators. The conference will examine the latest research and development in pathogenesis, diagnosis and treatment of the disease. As well as exceptional speaker presentations the meeting features 10 roundtable discussions. Each is led by an expert to provide you with a unique opportunity to debate the issues in areas such as the regulatory challenges for FDA approval, NASH and Diabetes and Preclinical models, to name just four.


More info can be found at


The programme can be found at


Speakers from Belgium are:

  1. SVEN FRANCQUE, Chairman, Division of Gastroenterology and Hepatology, Antwerp University Hospital, Belgium

Clinical Trial Design and also The adipose tissue-liver axis in NAFLD: implications for therapy and also NAFLD as a risk factor for cardiovascular disease

  1. ANJA GEERTS, Professor, Department of Gastroenterology and Hepatology, University of Ghent, Belgium

The pitfalls of bariatric surgery in NAFLD patients